- Core Earnings Per Share (EPS): $1.98, slightly above the estimated $1.95.
- Core Operating Margin: 32%, slightly below the estimated 33.1%.
- Revenue: $12.94 billion, beating the estimate of $12.56 billion.
- Alliance Revenue: $482 million, falling short of the estimated $493.4 million.
- Product Sales: $12.45 billion, surpassing the estimated $11.93 billion.
- R&D Expenses: $3.01 billion, higher than the estimated $2.71 billion.
- SG&A Expenses: $4.93 billion, exceeding the estimated $4.78 billion.
- Analyst Recommendations: 25 buys, 7 holds, and 1 sell.
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the Smartkarma Smart Scores for AstraZeneca PLC, the company has received varying ratings across different factors. With a Growth score of 4 and a Momentum score of 4, the outlook for AstraZeneca in the long term appears positive. The high Growth score indicates potential for expansion and development, while the strong Momentum score suggests the company’s ability to maintain its current trajectory.
However, AstraZeneca’s Value score of 2 and Resilience score of 2 do raise some concerns. The lower Value score may indicate that the company is not currently considered undervalued, while the Resilience score suggests a moderate level of vulnerability to economic and market fluctuations. Despite these lower scores, AstraZeneca’s Dividend score of 3 signifies a stable dividend policy, providing some reassurance to investors. Overall, AstraZeneca PLC, operating in various therapeutic areas, remains focused on researching, manufacturing, and selling pharmaceutical and medical products for the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
